Kindora
FeaturesSocial Enterprise FundingPricingDevelopers
AboutLive Demos
Sign InSign Up
    Kindora
    FeaturesSocial Enterprise FundingPricingDevelopers
    AboutLive Demos
    Sign InSign Up
    1. Home
    3. Foundations
    5. Alzheimer'S Disease Research Foundation
    Alzheimer'S Disease Research Foundation logo

    Alzheimer'S Disease Research Foundation

    ActiveMedical Research
    WELLESLEY HILLS, MAWebsite7812373800

    About Alzheimer'S Disease Research Foundation

    Fund and accelerate research to understand, prevent, and find therapies for Alzheimer's disease.

    Focus Areas

    Alzheimer's Genome ProjectWhole Genome SequencingGenes to Therapy / Stem Cell ScreeningImmune system structures & processesMicrobiome interactionPathological pathways & systemsTherapeutic strategies & drug discoveryIdentification

    Who They Fund

    people living with Alzheimer's diseaseolder adults (including cognitively normal and affected)neuroscience / biomedical research community (basic and translational researchers)

    About Alzheimer'S Disease Research Foundation

    The Alzheimer's Disease Research Foundation backs targeted biomedical research on Alzheimer's disease, with a clear emphasis on genetics, immune mechanisms, the microbiome, and therapy development. In the recent grants list, its largest awards went to Massachusetts General Hospital for The CureAlz Alzheimer's Genome Project, including $1,955,000 in both 2023 and 2024. That scale is matched by repeated support for collaborative research structures rather than one-off project grants alone. The foundation also funds investigator-led work on microglia, APOE biology, blood-brain barrier and fluid-clearance dynamics, tau pathology, and therapeutic strategies. Its portfolio shows a strong preference for coordinated science that can connect discovery to translational next steps. Grants to Brigham and Women's Hospital, Washington University, Boston Children's Hospital, and the University of California San Diego point to recurring investment in molecular and cell-based questions tied to Alzheimer's pathology. The foundation's stated beneficiary groups include people living with Alzheimer's disease, older adults, and the neuroscience and biomedical research community, reflecting a research-first model aimed at understanding, preventing, and finding therapies for the disease.

    What Alzheimer'S Disease Research Foundation Funds

    A major theme is genetics and disease architecture. Massachusetts General Hospital received $1,955,000 for The CureAlz Alzheimer's Genome Project, showing the foundation's commitment to large-scale discovery work on risk factors and biological pathways. It also supports immune and microglial research. Brigham and Women's Hospital received $431,250 in 2024 for a new model of microglia genetic perturbation in vivo to screen risk factors associated with Alzheimer's disease, while Boston Children's Hospital received $344,085 for peripheral inflammation and myeloid cell function. Another focus is APOE biology and tau-related mechanisms. Washington University received $345,000 for the APOE Consortium project on APOE isoforms in immune responses in a model of tauopathy, and Massachusetts General Hospital received $287,169 for work asking how soluble tau species replicate. The microbiome and brain-entry/exit systems also appear repeatedly, including grants for diet-microbe interactions, microbial profiling, blood-brain barrier changes, and CSF and lymph analysis.

    How Alzheimer'S Disease Research Foundation Gives

    Financial Snapshot

    Annual Giving

    $33.8M

    Total Assets

    $43.2M

    Total Revenue

    $56.7M

    Total Expenses

    $46.2M

    Typical Grant Size

    Most grants fall between $173K and $245K, with a median of $201K.

    25th Percentile

    $173K

    Median

    $201K

    75th Percentile

    $245K

    Geographic Reach

    National16 states funded
    Funding intensity
    Low
    High
    Headquarters

    Leadership

    MARGARET E SMITH

    Accepts unsolicited proposals

    Deep Analysis

    Unlock Deep Analysis

    Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.

    Get Started Free

    Similar Funders

    See Similar Funders

    Free Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.

    Get Started Free

    Explore related grant guides

    Health GrantsHealth Grants in MassachusettsGrants in Massachusetts

    Want a Personalized Pitch for Alzheimer'S Disease Research Foundation?

    Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.

    Get Started FreeView Pricing
    Free plan available
    No contracts
    Cancel anytime
    Free Weekly Newsletter

    The Grant Brief

    Weekly grant intelligence for social impact leaders. Curated opportunities, funding trends, and strategic insights — free.

    Join 500+ social impact leaders. Unsubscribe anytime. Privacy Policy

    Trusted by mission-driven teams at organizations nationwide

    Kindora Logo

    Funders you can find. Funders you can reach.

    Get The Grant Brief — free weekly grant intelligence

    Quick Links

    • Features
    • Social Enterprise Funding
    • About Us
    • Where our information comes from
    • Success Stories
    • Mission
    • How It Works
    • Pricing
    • Developers
    • Sales deck
    • Live Demand Wall
    • Philanthropy Jobs
    • Nonprofit Compensation
    • Invest in Kindora
    • Live demo (every plan)
    • Individual prospecting demoBeta
    • Blog
    • FAQ
    • Getting Started

    Connect With Us

    LinkedIn

    Find Grants

    Grants by CauseGrants by StateFoundations by CityEducation GrantsHealth GrantsArts & Culture GrantsEnvironment GrantsCommunity Development GrantsYouth Development Grants

    © 2026 Kindora. All rights reserved.

    Privacy PolicyTerms of ServiceSystem Status
    EIN (Tax ID): 52-2396428Latest Form 990: 2026Total assets: $43.2M4 filings on recordFind their full 990 filing →
    See If You're a Fit — FreeFree account · instant fit score · similar funders

    Funding Style

    targeted biomedical research grantsmulti-project consortium supporttranslational/therapeutic developmentresearch infrastructure & biobank creation

    Topics

    microglia genetics and functional perturbationAPOE isoforms and immune cell crosstalkblood-brain barrier / CSF-lymph clearance dynamicsgut microbiome–brain interactions and diet-microbe modulationtau pathology and prion-like tau replication mechanismsneuroimmune activation & peripheral inflammation effectsbiomarker & tool development (CSF/blood assays, enhancer mapping, iPSC/fibroblast bank)

    Typical awards cluster in the low-to-mid $200,000 range, with a p25 of $172,500, a median of $201,250, and a p75 of $245,106. The recent list also shows a higher tier of consortium and genome-project funding above that range, including multiple awards around $287,500 to $345,000 and two $1,955,000 genome-project grants. The same institutions appear across 2023 and 2024, including Massachusetts General Hospital, Washington University, Brigham and Women's Hospital, Boston Children's Hospital, and University of California San Diego, which points to recurring support rather than isolated awards. The organization does not fund individuals and is not using program-related investments in the data provided. Unsolicited applications are not accepted in the listed research grant and consortium programs.

    Where Alzheimer'S Disease Research Foundation Makes Grants

    Grantmaking is national, and every recent grant in the dataset went to a U.S. recipient. Massachusetts is the most frequent recipient state, accounting for 34% of grants. Boston and Cambridge appear repeatedly, including Boston, Charlestown, and Cambridge institutions, while additional awards went to St Louis, La Jolla, New York, Chicago, Los Angeles, Dallas, Irvine, and San Diego. The pattern is concentrated in major research hubs rather than a single region.

    Frequently Asked Questions About Alzheimer'S Disease Research Foundation

    What types of research does the foundation support?

    Its stated focus areas center on Alzheimer's disease research, including the Alzheimer's Genome Project, Genes to Therapy / Stem Cell Screening, Immune System Structures & Processes, Microbiome, Therapeutic Strategies & Drug Discovery, and Identification. Recent grants also show support for microglia, APOE, blood-brain barrier, tau, and neuroimmune work.

    How large are typical grants?

    The grant size distribution is centered in the low-to-mid $200,000 range: p25 is $172,500, median is $201,250, and p75 is $245,106. Recent awards also include larger consortium and genome-project grants above $300,000 and $1,955,000 awards for The CureAlz Alzheimer's Genome Project.

    Does the foundation accept unsolicited applications?

    No. The listed research grant process, Brain Entry & Exit Consortium, Microbiome Consortium, Neuroimmune Consortium, and several other active programs are marked as not accepting unsolicited applications.

    Which institutions appear repeatedly in recent grantmaking?

    Massachusetts General Hospital, Washington University, Brigham and Women's Hospital, Boston Children's Hospital, and University of California San Diego each appear more than once in the recent grants list, with grants in both 2023 and 2024 for some of those institutions.

    Where does most of the grantmaking go?

    Massachusetts is the top recipient state by grant count, with 34% of grants going to recipients there. Recent awards also land in California, Missouri, Illinois, New York, and Texas, but the strongest concentration is in Massachusetts research institutions.

    Latest 990 Filing

    2026

    Source: IRS Form 990-PF, fiscal year 2026.

    Open Grant Opportunities

    Current and upcoming funding from Alzheimer'S Disease Research Foundation that your nonprofit may be able to apply for.

    Open nowRolling cadenceMay not accept unsolicited proposals

    General Research Grant Program

    Genetic risk factorsBiomarkers and diagnosticsStudies of risk and resilience+16 more

    Who can apply: CureAlz provides funding to not-for-profit institutions around the world. Letters of inquiry are welcome from qualified scientists, but unsolicited proposals are not considered. For-profit entities may be considered only on an investment basis and must demonstrate financial viability. Animal research must meet institutional care standards; human-subject research must have IRB approval. Projects should use both male and female animals/humans/samples absent compelling scientific justification.

    Deadline: Accepted and reviewed on a rolling basis; there is no set timeline for applications, funding decisions, or funding initiation.

    View & apply

    Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.

    Create a free account

    Deadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.

    Recent Grants

    Most recent grants reported to the IRS.

    RecipientLocationAmountYearPurpose
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$1,955,0002026THE CUREALZ ALZHEIMER'S GENOME PROJECT
    BRIGHAM AND WOMEN'S HOSPITALBOSTON, MA$575,0002026APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS
    BRIGHAM AND WOMEN'S HOSPITALBOSTON, MA$431,2502026A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE
    WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITYNEW YORK, NY$402,5002026SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES
    UNIVERSITY OF MICHIGANANN ARBOR, MI$402,5002026NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES
    UNIVERSITY OF CALIFORNIA IRVINEIRVINE, CA$402,4922026PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE
    UNIVERSITY OF MICHIGANANN ARBOR, MI$398,5212026UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES
    WASHINGTON UNIVERSITY IN ST LOUISST LOUIS, MO$345,0002026APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS
    WASHINGTON UNIVERSITY IN ST LOUISST LOUIS, MO$345,0002026BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE
    WASHINGTON UNIVERSITY IN ST LOUISST LOUIS, MO$345,0002026BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE
    BOSTON CHILDREN'S HOSPITALBOSTON, MA$344,5282026NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE
    THE MCLEAN HOSPITAL CORPORATIONBELMONT, MA$327,5012026EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS
    DUKE UNIVERSITY SCHOOL OF MEDICINEDURHAM, NC$320,0332026UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$300,0002026UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY
    NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKEBETHESDA, MD$287,6732026BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS
    NEW YORK UNIVERSITY SCHOOL OF MEDICINENEW YORK, NY$287,5002026NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD
    UNIVERSITY OF ROCHESTERROCHESTER, NY$287,5002026BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE?
    WASHINGTON UNIVERSITY IN ST LOUISST LOUIS, MO$287,5002026BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES
    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA$287,5002026BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE?
    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA$287,5002026NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$287,5002026BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE
    STANFORD UNIVERSITYREDWOOD CITY, CA$287,5002026BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE
    WASHINGTON UNIVERSITY IN ST LOUISST LOUIS, MO$287,4992026BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE
    UNIVERSITY OF CALIFORNIA IRVINEIRVINE, CA$287,4902026NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS
    MASSACHUSETTS INSTITUTE OF TECHNOLOGYCAMBRIDGE, MA$287,4772026BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS
    UNIVERSITY OF CALIFORNIA DAVISDAVIS, CA$286,4662026NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION
    UNIVERSITY OF PENNSYLVANIAPHILADELPHIA, PA$284,6782026APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY
    UNIVERSITY OF ALABAMA AT BIRMINGHAMBIRMINGHAM, AL$271,3752026EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK
    BOSTON CHILDREN'S HOSPITALBOSTON, MA$264,5002026BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT)
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$258,7502026EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT)
    UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA$258,7502026THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT)
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$258,7502026ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT)
    WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITYNEW YORK, NY$258,7502026A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT)
    GLADSTONE INSTITUTESSAN FRANCISCO, CA$258,6152026DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT)
    GLADSTONE INSTITUTESSAN FRANCISCO, CA$258,5732026DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT)
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$252,0762026MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY
    THE BROAD INSTITUTE INCCAMBRIDGE, MA$230,0002026INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS
    PRESIDENT AND FELLOWS OF HARVARD COLLEGECAMBRIDGE, MA$230,0002026MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY
    MAYO CLINIC JACKSONVILLEJACKSONVILLE, FL$230,0002026UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGOLA JOLLA, CA$230,0002026APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME
    MASSACHUSETTS GENERAL HOSPITALBOSTON, MA$230,0002026ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE
    UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTERDALLAS, TX$230,0002026ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
    UNIVERSITY OF CALIFORNIA IRVINEIRVINE, CA$230,0002026ENGINEERED CAR-MACROPHAGES TO CLEAR TAU
    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAINEW YORK, NY$230,0002026INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY
    BRIGHAM AND WOMEN'S HOSPITALBOSTON, MA$228,9002026DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA?
    NEW YORK UNIVERSITY SCHOOL OF MEDICINENEW YORK, NY$210,9622026MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE
    DUKE UNIVERSITY SCHOOL OF MEDICINEDURHAM, NC$204,6562026CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE
    UNIVERSITY OF MICHIGANANN ARBOR, MI$201,2512026MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD
    AUGUSTA UNIVERSITY RESEARCH INSTITUTE INCAUGUSTA, GA$201,2502026THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY
    UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA$201,2502026ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD

    MASSACHUSETTS GENERAL HOSPITAL

    $1,955,000
    BOSTON, MA2026

    THE CUREALZ ALZHEIMER'S GENOME PROJECT

    BRIGHAM AND WOMEN'S HOSPITAL

    $575,000
    BOSTON, MA2026

    APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS

    BRIGHAM AND WOMEN'S HOSPITAL

    $431,250
    BOSTON, MA2026

    A NEW MODEL OF MICROGLIA GENETIC PERTURBATION IN VIVO TO SCREEN ALL RISK FACTORS ASSOCIATED WITH ALZHEIMER'S DISEASE

    WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

    $402,500
    NEW YORK, NY2026

    SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES

    UNIVERSITY OF MICHIGAN

    $402,500
    ANN ARBOR, MI2026

    NON-INVASIVE MODULATION OF MICROGLIA GENE EXPRESSION USING PERIPHERALLY ADMINISTERED ANTIBODY CONJUGATES

    UNIVERSITY OF CALIFORNIA IRVINE

    $402,492
    IRVINE, CA2026

    PROTEOMIC SIGNATURES OF CEREBROVASCULAR NEUROPATHOLOGY IN DOWN SYNDROME WITH ALZHEIMER DISEASE

    UNIVERSITY OF MICHIGAN

    $398,521
    ANN ARBOR, MI2026

    UTILIZING HETEROGENEOUS MOUSE MODELS TO DISCOVER MECHANISMS UNDERLYING CALORIC RESTRICTION (CR) ON COGNITIVE OUTCOMES

    WASHINGTON UNIVERSITY IN ST LOUIS

    $345,000
    ST LOUIS, MO2026

    APOE CONSORTIUM: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS

    WASHINGTON UNIVERSITY IN ST LOUIS

    $345,000
    ST LOUIS, MO2026

    BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE

    WASHINGTON UNIVERSITY IN ST LOUIS

    $345,000
    ST LOUIS, MO2026

    BAC: IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN ALZHEIMER'S DISEASE

    BOSTON CHILDREN'S HOSPITAL

    $344,528
    BOSTON, MA2026

    NIC: EFFECTS OF PERIPHERAL INFLAMMATION ON MYELOID CELL FUNCTION IN ALZHEIMER'S DISEASE

    THE MCLEAN HOSPITAL CORPORATION

    $327,501
    BELMONT, MA2026

    EXPANDING POSTMORTEM BRAIN RESOURCES FOR ALZHEIMER'S DISEASE IN DIVERSE POPULATIONS

    DUKE UNIVERSITY SCHOOL OF MEDICINE

    $320,033
    DURHAM, NC2026

    UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES

    MASSACHUSETTS GENERAL HOSPITAL

    $300,000
    BOSTON, MA2026

    UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY

    NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE

    $287,673
    BETHESDA, MD2026

    BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS

    NEW YORK UNIVERSITY SCHOOL OF MEDICINE

    $287,500
    NEW YORK, NY2026

    NIC: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO AD

    UNIVERSITY OF ROCHESTER

    $287,500
    ROCHESTER, NY2026

    BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE?

    WASHINGTON UNIVERSITY IN ST LOUIS

    $287,500
    ST LOUIS, MO2026

    BAC: BRAIN REGION AND CELL-TYPE SPECIFIC AGING FROM ACCELERATED TO RESILIENT TRAJECTORIES

    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO

    $287,500
    LA JOLLA, CA2026

    BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE?

    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO

    $287,500
    LA JOLLA, CA2026

    NIC: MECHANISMS MEDIATING MICROGLIA SENSING OF PERIPHERAL INFLAMMATION

    MASSACHUSETTS GENERAL HOSPITAL

    $287,500
    BOSTON, MA2026

    BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE

    STANFORD UNIVERSITY

    $287,500
    REDWOOD CITY, CA2026

    BAC: CHOROID PLEXUS AGING AND ALZHEIMER'S DISEASE

    WASHINGTON UNIVERSITY IN ST LOUIS

    $287,499
    ST LOUIS, MO2026

    BAC: ESTABLISHING ISOGENIC MODELS OF HUMAN NEURON AGING AND PATHWAYS RELEVANT FOR ALZHEIMER'S DISEASE

    UNIVERSITY OF CALIFORNIA IRVINE

    $287,490
    IRVINE, CA2026

    NIC: EXAMINING THE IMPACT OF PERIPHERALLY DERIVED HUMAN MACROPHAGES IN AD PATHOGENESIS

    MASSACHUSETTS INSTITUTE OF TECHNOLOGY

    $287,477
    CAMBRIDGE, MA2026

    BAC: INVESTIGATING LIPIDOMIC PERTURBATIONS IN THE CSF WITH AGE AND ALZHEIMER'S DISEASE PROGRESSION: TOWARD MECHANISTIC INSIGHTS AND ACCESSIBLE LIPID BIOMARKERS

    UNIVERSITY OF CALIFORNIA DAVIS

    $286,466
    DAVIS, CA2026

    NIC: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION

    UNIVERSITY OF PENNSYLVANIA

    $284,678
    PHILADELPHIA, PA2026

    APOE CONSORTIUM: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY

    UNIVERSITY OF ALABAMA AT BIRMINGHAM

    $271,375
    BIRMINGHAM, AL2026

    EXPANDING DEEP SOUTH INCLUSION IN THE UAB ADRC NEUROPATHOLOGY CORE BRAIN BANK

    BOSTON CHILDREN'S HOSPITAL

    $264,500
    BOSTON, MA2026

    BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE (SUPPLEMENT)

    MASSACHUSETTS GENERAL HOSPITAL

    $258,750
    BOSTON, MA2026

    EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS (CFSF SUPPLEMENT)

    UNIVERSITY OF VIRGINIA

    $258,750
    CHARLOTTESVILLE, VA2026

    THE ROLE OF PLANAR CELL POLARITY PROTEINS IN TAU OLIGOMER-INDUCED SYNAPSE DEGENERATION (CFSF SUPPLEMENT)

    MASSACHUSETTS GENERAL HOSPITAL

    $258,750
    BOSTON, MA2026

    ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING (CFSF SUPPLEMENT)

    WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY

    $258,750
    NEW YORK, NY2026

    A THREE-DIMENSIONAL TISSUE MODEL LINKING TAU TANGLES, AB AND MICROGLIAL CD33- ISOFORM STATE TO GENE- AND ISOFORM-EXPRESSION DYSREGULATION (CFSF SUPPLEMENT)

    GLADSTONE INSTITUTES

    $258,615
    SAN FRANCISCO, CA2026

    DECODING PROTEIN TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER TO ENABLE NEW ALZHEIMER'S THERAPIES (CFSF SUPPLEMENT)

    GLADSTONE INSTITUTES

    $258,573
    SAN FRANCISCO, CA2026

    DEVELOPING CELL-TYPE-SPECIFIC ENHANCER-AAV VECTORS TO CHARACTERIZE AND RESTORE AB- AND TAU-DEPENDENT CIRCUIT AND COGNITIVE DEFICITS IN HUMANIZED ALZHEIMER'S MOUSE MODELS (CFSF SUPPLEMENT)

    MASSACHUSETTS GENERAL HOSPITAL

    $252,076
    BOSTON, MA2026

    MENOPAUSE AND RELATED MIDLIFE RISK FACTORS AND THEIR IMPACT ON PATHOLOGY AND COGNITION - THE WHIMSYAD STUDY

    THE BROAD INSTITUTE INC

    $230,000
    CAMBRIDGE, MA2026

    INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS

    PRESIDENT AND FELLOWS OF HARVARD COLLEGE

    $230,000
    CAMBRIDGE, MA2026

    MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY

    MAYO CLINIC JACKSONVILLE

    $230,000
    JACKSONVILLE, FL2026

    UNRAVELING MIXED PATHOLOGY AND ITS IMPACT ON THE PROTEOME IN ALZHEIMER'S DISEASE

    REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO

    $230,000
    LA JOLLA, CA2026

    APP GENE DOSE-MEDIATED DYSREGULATION OF THE ENDOLYSOSOMAL NETWORK ACTS COMPROMISE SYNAPTIC STRUCTURE AND FUNCTION LEADING TO ALZHEIMER DISEASE IN DOWN SYNDROME

    MASSACHUSETTS GENERAL HOSPITAL

    $230,000
    BOSTON, MA2026

    ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE

    UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER

    $230,000
    DALLAS, TX2026

    ENGINEERED CAR-MACROPHAGES TO CLEAR TAU

    UNIVERSITY OF CALIFORNIA IRVINE

    $230,000
    IRVINE, CA2026

    ENGINEERED CAR-MACROPHAGES TO CLEAR TAU

    ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

    $230,000
    NEW YORK, NY2026

    INVESTIGATING THE PATHOGENETIC ROLE OF MICROGLIAL MEF2C IN ALZHEIMER'S DISEASE ACROSS THE LIFESPAN: DEVELOPMENTAL PRIMING VS. ADULT RESPONSE TO INJURY

    BRIGHAM AND WOMEN'S HOSPITAL

    $228,900
    BOSTON, MA2026

    DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA?

    NEW YORK UNIVERSITY SCHOOL OF MEDICINE

    $210,962
    NEW YORK, NY2026

    MECHANISMS OF ASTROCYTE-DERIVED LIPID TOXICITY IN ALZHEIMER'S DISEASE

    DUKE UNIVERSITY SCHOOL OF MEDICINE

    $204,656
    DURHAM, NC2026

    CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE

    UNIVERSITY OF MICHIGAN

    $201,251
    ANN ARBOR, MI2026

    MORPHOLOGICAL, ELECTROPHYSIOLOGICAL, AND TRANSCRIPTIONAL CHARACTERIZATION OF SINGLE NEURONS FROM RESILIENT AND SUSCEPTIBLE MODELS OF HUMAN AD

    AUGUSTA UNIVERSITY RESEARCH INSTITUTE INC

    $201,250
    AUGUSTA, GA2026

    THE IMPACT OF SOLUBLE DIETARY FIBER ON TAU-MEDIATED NEURODEGENERATION IN A MOUSE MODEL OF TAUOPATHY

    UNIVERSITY OF VIRGINIA

    $201,250
    CHARLOTTESVILLE, VA2026

    ELUCIDATING THE ROLE OF EMERGING GENOMIC STRESS SENSORS IN AD